Download PDF

Register to download the report. Already a member?

Sign Up


67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:

Ipsen: A Track Record of Excellence in Ireland

These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products.

French specialty-driven pharma outfit Ipsen has seen significant success in recent years, with global group sales totalling EUR 1.58 billion in 2016 - an 11.8 percent increase on the previous year -, 4,900 employees, operations in 115 countries, seven industrial sites and three major R&D centers. The group stands to grow even further with the recent acquisition of pancreatic cancer drug Onivyde® from Merrimack Pharmaceuticals, ambitious plans for further international expansion and the promise of a new global CEO in the near future.

Irish operations are integral to Ipsen’s future successes. The group’s manufacturing site in Dublin, first opened in 1989, is its center for the production and development of peptide active pharmaceutical ingredients (APIs). James Byrne, VP site for Ipsen Manufacturing in Ireland explains: “This is one of Ipsen’s key manufacturing facilities globally. Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global revenues of EUR 1.4 billion in 2015.” Furthermore, Byrne notes that “sales of Somatuline® have been growing rapidly: more than 30 percent in 2015 and close to 40 percent in H1 2016. This places a significant strain on our manufacturing – but it is a very nice challenge to have!”



Most Read

Download PDF

First Name:

Last Name: